Finkelstein Thompson is investigating claims on behalf of individuals consuming the drug Pradaxa who may have experienced adverse bleeding events, i.e. hemorrhages.  Pradaxa is used to prevent strokes among patients with a dangerous irregular heartbeat, called atrial fibrillation, that tends to mainly impact the elderly.  It is part of a new line of oral medicines called “direct thrombin inhibitors.” The United States Food and Drug Administration first approved Pradaxa in October 2010. 

In an article published on September 5, 2012 in an issue of the Journal of the American Medical Association (JAMA), and written by Thomas J. Moore and Curt D. Furberg, Pradaxa was noted as one of three drugs that received "Accelerated Approval" by the FDA in 2011. "Accelerated Approval" is a program that relies on preliminary but not definitive evidence of benefit. It was further noted in the article that because of the risk of side effects, and the potential compromise of drug safety that occurred because of the Accelerated Approval, there is a question as to whether the FDA should have approved the three drugs while "significant safety questions" remained unanswered.

Patients who experience bleeding on Pradaxa can be put on dialysis, but beginning dialysis is time-consuming. Patients who developed uncontrollable bleeding on Pradaxa suffered injuries such as cerebral hemorrhage, kidney bleeds and heart attacks.

If you believe you have been affected by Pradaxa, Finkelstein Thompson welcomes your inquiries. Finkelstein Thompson's Washington, D.C. office can be reached at (877) 337-1050 or at This email address is being protected from spam bots, you need Javascript enabled to view it .